Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Middle East and Africa Bronchiectasis Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991670
Published Content info 322 Pages
Delivery time: 1-2 business days
Price
Back to Top
Middle East and Africa Bronchiectasis Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 322 Pages
Description

Middle East and Africa bronchiectasis market is projected to register a healthy CAGR of 4.9% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Middle East and Africa Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generic), Route of Administration (Oral, Parenteral, and Inhalation), End User (Hospitals, Clinics, Home Health Care, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends & Forecast to 2028.

Some of the major factors contributing to the growth of Middle East and Africa bronchiectasis market are:

  • Raising number of smokers and consumption of alcohol
  • Availability of generic drugs in underdeveloped and developing countries

The key market players for Middle East and Africa bronchiectasis market are listed below:

  • Abbott
  • HERSILL
  • Inogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Ache Laboratories Farmaceuticos S.A.
  • Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DISEASE TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET DRUGS TYPE COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: LAWS AND REGULATIONS

6 EPIDEMIOLOGY

7 MARKET OVERVIEW

  • 7.1 DRIVERS
    • 7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
    • 7.1.2 GROWING GERIATRIC POPULATION
    • 7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
    • 7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
    • 7.1.5 GROWING DIAGNOSTIC RATE
  • 7.2 RESTRAINTS
    • 7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
    • 7.2.2 PRODUCT RECALLS
    • 7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
  • 7.3 OPPORTUNITIES
    • 7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE
    • 7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
    • 7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
  • 7.4 CHALLENGES
    • 7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
    • 7.4.2 LACK OF SKILLED PROFESSIONALS
    • 7.4.3 DIAGNOSITIC CHALLENGES

8 IMPACT OF COVID-19

  • 8.1 PRICE IMPACT
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 8.5 CONCLUSION

9 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISEASE TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-CF BRONCHIECTASIS
  • 9.3 CF BRONCHIECTASIS

10 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MILD TO MODERATE
  • 10.3 MODERATE TO SEVERE

11 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 TREATMENT
    • 11.2.1 ANTIBIOTICS
      • 11.2.1.1 MACROLIDE
        • 11.2.1.1.1 AZITHROMYCIN
        • 11.2.1.1.2 CLARITHROMYCIN
        • 11.2.1.1.3 OTHERS
      • 11.2.1.2 AMOXICILLIN
      • 11.2.1.3 CEPHALOSPORIN
        • 11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
        • 11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
      • 11.2.1.4 AMINOGLYCOSIDE
        • 11.2.1.4.1 GENTAMICIN
        • 11.2.1.4.2 TOBRAMYCIN
      • 11.2.1.5 FLUOROQUINOLONE
      • 11.2.1.6 TETRACYCLINS
      • 11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
      • 11.2.1.8 COMBINATION THERAPY
    • 11.2.2 CORTICOSTEROIDS
      • 11.2.2.1 BUDESONIDE
      • 11.2.2.2 FLUTICASONE
      • 11.2.2.3 MOMETASONE
      • 11.2.2.4 FLUNISOLIDE
      • 11.2.2.5 OTHERS
    • 11.2.3 BRONCHODILATORS
      • 11.2.3.1 LONG-ACTING BRONCHODILATORS
        • 11.2.3.1.1 FORMOTEROL
        • 11.2.3.1.2 TIOTROPIUM
        • 11.2.3.1.3 SALMETEROL
        • 11.2.3.1.4 OTHERS
      • 11.2.3.2 SHORT-ACTING BRONCHODILATORS
        • 11.2.3.2.1 ALBUTEROL
        • 11.2.3.2.2 LEVALBUTEROL
        • 11.2.3.2.3 OTHERS
    • 11.2.4 MUCUS THINNING MEDICINE
      • 11.2.4.1 CARBOCISTEINE
      • 11.2.4.2 BROMHEXINE
      • 11.2.4.3 OTHERS
    • 11.2.5 AIRWAY CLEARANCE DEVICES
      • 11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
      • 11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
      • 11.2.5.3 POSTURAL DRAINAGE
      • 11.2.5.4 OTHERS
    • 11.2.6 OXYGEN THERAPY
      • 11.2.6.1 OXYGEN CONCENTRATORS
      • 11.2.6.2 COMPRESSED GAS OXYGEN
      • 11.2.6.3 LIQUID OXYGEN
    • 11.2.7 SURGERY
      • 11.2.7.1 BRONCHOSCOPY
      • 11.2.7.2 LUNG TRANSPLANT
    • 11.2.8 OTHERS
  • 11.3 DIAGNOSIS
    • 11.3.1 CHEST CT SCAN
    • 11.3.2 SPUTUM TEST
    • 11.3.3 PULMONARY FUNCTION TEST
    • 11.3.4 X-RAY
    • 11.3.5 OTHERS

12 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DRUGS TYPE

  • 12.1 OVERVIEW
  • 12.2 BRANDED
  • 12.3 GENERICS

13 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION

  • 13.1 OVERVIEW
  • 13.2 INHALATION
  • 13.3 ORAL
    • 13.3.1 TABLETS
    • 13.3.2 CAPSULES
    • 13.3.3 OTHERS
  • 13.4 PARENTERAL
    • 13.4.1 INTRAVENOUS
    • 13.4.2 SUBCUTANEOUS
    • 13.4.3 OTHERS

14 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 CLINICS
  • 14.4 HOME HEALTHCARE
  • 14.5 OTHERS

15 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE PHARMACY
  • 15.5 OTHERS

16 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 MIDDLE EAST AND AFRICA
    • 16.2.1 SAUDI ARABIA
    • 16.2.2 SOUTH AFRICA
    • 16.2.3 UAE
    • 16.2.4 ISRAEL
    • 16.2.5 KUWAIT
    • 16.2.6 EGYPT
    • 16.2.7 REST OF MIDDLE EAST AND AFRICA

17 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: MEDDLE EAST AND AFRICA

18 SWOT

19 COMPANY PROFILES

  • 19.1 ASTRAZENECA
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 GLAXOSMITHKLINE PLC.
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENTS
  • 19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANALYSIS
    • 19.3.4 PRODUCT PORTFOLIO
    • 19.3.5 RECENT DEVELOPMENTS
  • 19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 PRODUCT PORTFOLIO
    • 19.4.5 RECENT DEVELOPMENTS
  • 19.5 NOVARTIS AG
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENTS
  • 19.6 ABBOTT
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 REVENUE ANALYSIS
    • 19.6.3 PRODUCT PORTFOLIO
    • 19.6.4 RECENT DEVELOPMENT
  • 19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 PRODUCT PORTFOLIO
    • 19.7.3 RECENT DEVELOPMENTS
  • 19.8 BAYER AG
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 REVENUE ANALYSIS
    • 19.8.3 PRODUCT PORTFOLIO
    • 19.8.4 RECENT DEVELOPMENTS
  • 19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENT
  • 19.10 CIPLA INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENTS
  • 19.11 COVIS PHARMA
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 PRODUCT PORTFOLIO
    • 19.11.3 RECENT DEVELOPMENT
  • 19.12 DR. REDDY'S LABORATORIES LTD.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 ELECTROMED, INC.
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 REVENUE ANALYSIS
    • 19.13.3 PRODUCT PORTFOLIO
    • 19.13.4 RECENT DEVELOPMENTS
  • 19.14 HERSILL
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 PRODUCT PORTFOLIO
    • 19.14.3 RECENT DEVELOPMENTS
  • 19.15 HOME OXYGEN COMPANY
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENT
  • 19.16 HORIZON THERAPEUTICS PLC
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENT
  • 19.17 INOGEN, INC.
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 REVENUE ANALYSIS
    • 19.17.3 PRODUCT PORTFOLIO
    • 19.17.4 RECENT DEVELOPMENTS
  • 19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENT
  • 19.19 MEDLINE INDUSTRIES, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENTS
  • 19.20 PFIZER INC.
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 PRODUCT PORTFOLIO
    • 19.20.4 RECENT DEVELOPMENTS
  • 19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 PRODUCT PORTFOLIO
    • 19.21.4 RECENT DEVELOPMENTS
  • 19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 REVENUE ANALYSIS
    • 19.22.3 PRODUCT PORTFOLIO
    • 19.22.4 RECENT DEVELOPMENTS
  • 19.23 TRUEDELL MEDICAL INTERNATIONAL
    • 19.23.1 COMPANY SNAPSHOT
    • 19.23.2 PRODUCT PORTFOLIO
    • 19.23.3 RECENT DEVELOPMENTS
  • 19.24 VIATRIS INC.
    • 19.24.1 COMPANY SNAPSHOT
    • 19.24.2 PRODUCT PORTFOLIO
    • 19.24.3 RECENT DEVELOPMENTS
  • 19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
    • 19.25.1 COMPANY SNAPSHOT
    • 19.25.2 REVENUE ANALYSIS
    • 19.25.3 PRODUCT PORTFOLIO
    • 19.25.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, PIPELINE ANALYSIS 57
  • TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS 58
  • TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC 74
  • TABLE 4 THE PRICE OF X-RAY MACHINE 78
  • TABLE 5 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 84
  • TABLE 6 MEDDLE EAST AND AFRICA NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 85
  • TABLE 7 MEDDLE EAST AND AFRICA CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 86
  • TABLE 8 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 90
  • TABLE 9 MEDDLE EAST AND AFRICA MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 91
  • TABLE 10 MEDDLE EAST AND AFRICA MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 92
  • TABLE 11 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 96
  • TABLE 12 MEDDLE EAST AND AFRICA TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION) 98
  • TABLE 13 MEDDLE EAST AND AFRICA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 98
  • TABLE 14 MEDDLE EAST AND AFRICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 99
  • TABLE 15 MEDDLE EAST AND AFRICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 99
  • TABLE 16 MEDDLE EAST AND AFRICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 100
  • TABLE 17 MEDDLE EAST AND AFRICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 100
  • TABLE 18 MEDDLE EAST AND AFRICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 101
  • TABLE 19 MEDDLE EAST AND AFRICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 102
  • TABLE 20 MEDDLE EAST AND AFRICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 102
  • TABLE 21 MEDDLE EAST AND AFRICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 103
  • TABLE 22 MEDDLE EAST AND AFRICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 104
  • TABLE 23 MEDDLE EAST AND AFRICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 104
  • TABLE 24 MEDDLE EAST AND AFRICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 105
  • TABLE 25 MEDDLE EAST AND AFRICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 106
  • TABLE 26 MEDDLE EAST AND AFRICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 107
  • TABLE 27 MEDDLE EAST AND AFRICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 107
  • TABLE 28 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 112
  • TABLE 29 MEDDLE EAST AND AFRICA BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 113
  • TABLE 30 MEDDLE EAST AND AFRICA GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 114
  • TABLE 31 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 118
  • TABLE 32 MEDDLE EAST AND AFRICA INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 119
  • TABLE 33 MEDDLE EAST AND AFRICA ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 120
  • TABLE 34 MEDDLE EAST AND AFRICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 120
  • TABLE 35 MEDDLE EAST AND AFRICA PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 121
  • TABLE 36 MEDDLE EAST AND AFRICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 121
  • TABLE 37 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION) 126
  • TABLE 38 MEDDLE EAST AND AFRICA HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 127
  • TABLE 39 MEDDLE EAST AND AFRICA CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 128
  • TABLE 40 MEDDLE EAST AND AFRICA HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 129
  • TABLE 41 MEDDLE EAST AND AFRICA OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 129
  • TABLE 42 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 133
  • TABLE 43 MEDDLE EAST AND AFRICA HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION) 134
  • TABLE 44 MEDDLE EAST AND AFRICA RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 135
  • TABLE 45 MEDDLE EAST AND AFRICA ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 135
  • TABLE 46 MEDDLE EAST AND AFRICA OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 136
  • TABLE 47 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION) 142
  • TABLE 48 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION) 147
  • TABLE 49 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 147
  • TABLE 50 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 147
  • TABLE 51 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 147
  • TABLE 52 MIDDLE EAST AND AFRICA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 148
  • TABLE 53 MIDDLE EAST AND AFRICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 148
  • TABLE 54 MIDDLE EAST AND AFRICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 149
  • TABLE 55 MIDDLE EAST AND AFRICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 149
  • TABLE 56 MIDDLE EAST AND AFRICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 149
  • TABLE 57 MIDDLE EAST AND AFRICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 149
  • TABLE 58 MIDDLE EAST AND AFRICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 59 MIDDLE EAST AND AFRICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 60 MIDDLE EAST AND AFRICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 61 MIDDLE EAST AND AFRICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 62 MIDDLE EAST AND AFRICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 63 MIDDLE EAST AND AFRICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 64 MIDDLE EAST AND AFRICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 65 MIDDLE EAST AND AFRICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 66 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 152
  • TABLE 67 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 152
  • TABLE 68 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 152
  • TABLE 69 MIDDLE EAST AND AFRICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 152
  • TABLE 70 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 153
  • TABLE 71 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 153
  • TABLE 72 SAUDI ARABIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 154
  • TABLE 73 SAUDI ARABIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 154
  • TABLE 74 SAUDI ARABIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 154
  • TABLE 75 SAUDI ARABIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 155
  • TABLE 76 SAUDI ARABIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 155
  • TABLE 77 SAUDI ARABIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 78 SAUDI ARABIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 79 SAUDI ARABIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 80 SAUDI ARABIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 81 SAUDI ARABIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 82 SAUDI ARABIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 83 SAUDI ARABIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 84 SAUDI ARABIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 85 SAUDI ARABIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 86 SAUDI ARABIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 87 SAUDI ARABIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 88 SAUDI ARABIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 89 SAUDI ARABIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 90 SAUDI ARABIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 159
  • TABLE 91 SAUDI ARABIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 159
  • TABLE 92 SAUDI ARABIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 159
  • TABLE 93 SAUDI ARABIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 160
  • TABLE 94 SAUDI ARABIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 160
  • TABLE 95 SOUTH AFRICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 161
  • TABLE 96 SOUTH AFRICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 161
  • TABLE 97 SOUTH AFRICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 161
  • TABLE 98 SOUTH AFRICA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 162
  • TABLE 99 SOUTH AFRICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 162
  • TABLE 100 SOUTH AFRICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 101 SOUTH AFRICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 102 SOUTH AFRICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 103 SOUTH AFRICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 104 SOUTH AFRICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 164
  • TABLE 105 SOUTH AFRICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 164
  • TABLE 106 SOUTH AFRICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 164
  • TABLE 107 SOUTH AFRICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 164
  • TABLE 108 SOUTH AFRICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 109 SOUTH AFRICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 110 SOUTH AFRICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 111 SOUTH AFRICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 112 SOUTH AFRICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 166
  • TABLE 113 SOUTH AFRICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 166
  • TABLE 114 SOUTH AFRICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 166
  • TABLE 115 SOUTH AFRICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 166
  • TABLE 116 SOUTH AFRICA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 167
  • TABLE 117 SOUTH AFRICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 167
  • TABLE 118 UAE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 168
  • TABLE 119 UAE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 168
  • TABLE 120 UAE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 168
  • TABLE 121 UAE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 169
  • TABLE 122 UAE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 169
  • TABLE 123 UAE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 170
  • TABLE 124 UAE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 170
  • TABLE 125 UAE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 170
  • TABLE 126 UAE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 170
  • TABLE 127 UAE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 128 UAE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 129 UAE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 130 UAE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 171
  • TABLE 131 UAE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 172
  • TABLE 132 UAE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 172
  • TABLE 133 UAE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 172
  • TABLE 134 UAE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 172
  • TABLE 135 UAE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 173
  • TABLE 136 UAE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 173
  • TABLE 137 UAE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 173
  • TABLE 138 UAE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 173
  • TABLE 139 UAE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 174
  • TABLE 140 UAE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 174
  • TABLE 141 ISRAEL BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 175
  • TABLE 142 ISRAEL BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 175
  • TABLE 143 ISRAEL BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 175
  • TABLE 144 ISRAEL TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 176
  • TABLE 145 ISRAEL TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 176
  • TABLE 146 ISRAEL TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 147 ISRAEL TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 148 ISRAEL TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 149 ISRAEL TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 177
  • TABLE 150 ISRAEL TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 178
  • TABLE 151 ISRAEL TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 178
  • TABLE 152 ISRAEL TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 178
  • TABLE 153 ISRAEL TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 178
  • TABLE 154 ISRAEL TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 179
  • TABLE 155 ISRAEL TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 179
  • TABLE 156 ISRAEL TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 179
  • TABLE 157 ISRAEL DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 179
  • TABLE 158 ISRAEL BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 180
  • TABLE 159 ISRAEL BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 180
  • TABLE 160 ISRAEL ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 180
  • TABLE 161 ISRAEL PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 180
  • TABLE 162 ISRAEL BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 181
  • TABLE 163 ISRAEL BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 181
  • TABLE 164 KUWAIT BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 182
  • TABLE 165 KUWAITT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 182
  • TABLE 166 KUWAIT BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 182
  • TABLE 167 KUWAIT TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 183
  • TABLE 168 KUWAIT TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 183
  • TABLE 169 KUWAIT TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 184
  • TABLE 170 KUWAIT TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 184
  • TABLE 171 KUWAIT TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 184
  • TABLE 172 KUWAIT TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 184
  • TABLE 173 KUWAIT TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 185
  • TABLE 174 KUWAIT TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 185
  • TABLE 175 KUWAIT TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 185
  • TABLE 176 KUWAIT TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 185
  • TABLE 177 KUWAIT TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 178 KUWAIT TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 179 KUWAIT TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 180 KUWAIT DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 186
  • TABLE 181 KUWAIT BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 187
  • TABLE 182 KUWAIT BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 187
  • TABLE 183 KUWAIT ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 187
  • TABLE 184 KUWAIT PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 187
  • TABLE 185 KUWAIT BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 188
  • TABLE 186 KUWAIT BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 188
  • TABLE 187 EGYPT BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 189
  • TABLE 188 EGYPT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 189
  • TABLE 189 EGYPT BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 189
  • TABLE 190 EGYPT TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 190
  • TABLE 191 EGYPT TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 190
  • TABLE 192 EGYPT TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 191
  • TABLE 193 EGYPT TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 191
  • TABLE 194 EGYPT TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 191
  • TABLE 195 EGYPT TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 191
  • TABLE 196 EGYPT TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 197 EGYPT TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 198 EGYPT TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 199 EGYPT TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 192
  • TABLE 200 EGYPT TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 193
  • TABLE 201 EGYPT TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 193
  • TABLE 202 EGYPT TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 193
  • TABLE 203 EGYPT DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 193
  • TABLE 204 EGYPT BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 194
  • TABLE 205 EGYPT BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 194
  • TABLE 206 EGYPT ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 194
  • TABLE 207 EGYPT PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 194
  • TABLE 208 EGYPT BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 195
  • TABLE 209 EGYPT BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 195
  • TABLE 210 REST OF MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 196

LIST OF FIGURES

  • FIGURE 1 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: SEGMENTATION 40
  • FIGURE 2 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET : DATA TRIANGULATION 43
  • FIGURE 3 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: DROC ANALYSIS 44
  • FIGURE 4 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: MEDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 45
  • FIGURE 5 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS 45
  • FIGURE 6 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING 46
  • FIGURE 7 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS 47
  • FIGURE 8 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID 48
  • FIGURE 9 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS 49
  • FIGURE 10 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID 50
  • FIGURE 11 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: SEGMENTATION 54
  • FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 55
  • FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET IN 2021 & 2028 55
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET 65
  • FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050 67
  • FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019) 67
  • FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS 73
  • FIGURE 18 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021 81
  • FIGURE 19 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION) 82
  • FIGURE 20 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028) 82
  • FIGURE 21 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE 83
  • FIGURE 22 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY SEVERITY, 2021 87
  • FIGURE 23 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION) 88
  • FIGURE 24 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028) 88
  • FIGURE 25 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE 89
  • FIGURE 26 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY TYPE, 2021 93
  • FIGURE 27 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION) 94
  • FIGURE 28 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028) 94
  • FIGURE 29 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE 95
  • FIGURE 30 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021 109
  • FIGURE 31 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION) 110
  • FIGURE 32 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028) 110
  • FIGURE 33 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE 111
  • FIGURE 34 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 115
  • FIGURE 35 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 116
  • FIGURE 36 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028) 116
  • FIGURE 37 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 117
  • FIGURE 38 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY END USER, 2021 123
  • FIGURE 39 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION) 124
  • FIGURE 40 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028) 124
  • FIGURE 41 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE 125
  • FIGURE 42 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021 130
  • FIGURE 43 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 131
  • FIGURE 44 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 131
  • FIGURE 45 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 132
  • FIGURE 46 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 137
  • FIGURE 47 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 139
  • FIGURE 48 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 139
  • FIGURE 49 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 140
  • FIGURE 50 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 140
  • FIGURE 51 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 142
  • FIGURE 52 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 144
  • FIGURE 53 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 144
  • FIGURE 54 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 145
  • FIGURE 55 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 145
  • FIGURE 56 MEDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 196
Back to Top